Literature DB >> 17163276

Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.

Silke Ewald1, Johannes vor dem Esche, Sakir Uen, Fabian Neikes, Hans Vetter, Thomas Mengden.   

Abstract

OBJECTIVES: This subanalysis of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study in patients with essential hypertension assessed the relationship between the frequency of blood pressure self-measurement (BPSM) and the response to blood pressure (BP)-lowering therapy with olmesartan medoxomil, and the number of BP readings per week necessary to detect a mean systolic or diastolic BP reduction > or =5mm Hg.
METHODS: A total of 53 patients with essential hypertension received treatment with olmesartan medoxomil 10, 20 or 40 mg daily for 12 weeks. BPSM was performed for the first 9 weeks using a TensioPhone TP2 device. Patients were instructed to measure BP at least twice daily (morning and evening).
RESULTS: After the first 9 weeks of the 12-week treatment period, the extent of BP reduction correlated with the number of BPSMs. Systolic/diastolic BP reductions in patients with a 100% adherence to at least two BP measurements daily were -16.6/-8.0mm Hg compared with -0.2/-3.3mm Hg in patients with only a 75% adherence to at least one BP measurement daily. Obtaining five home BP readings per week resulted in a sensitivity of 94.8% and a specificity of 90.0% to detect a BP reduction of > or =5mm Hg.
CONCLUSION: Patients adhering to the instructions for BPSM (at least two measurements daily) had a better response to antihypertensive treatment with olmesartan medoxomil. Whether BPSM per se resulted in an improved adherence to therapy or whether the number of recordings was an indicator of already existing adherence remains to be determined. Obtaining at least five home BP readings per week was identified as the threshold for correctly predicting response to olmesartan medoxomil treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163276     DOI: 10.2165/00044011-200626080-00002

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  24 in total

1.  Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial.

Authors:  Y Imai; T Ohkubo; A Hozawa; I Tsuji; M Matsubara; T Araki; K Chonan; M Kikuya; H Satoh; S Hisamichi; K Nagai
Journal:  J Hypertens       Date:  2001-02       Impact factor: 4.844

Review 2.  ABC of hypertension: Blood pressure measurement. Part IV-automated sphygmomanometry: self blood pressure measurement.

Authors:  E O'Brien; G Beevers; G Y Lip
Journal:  BMJ       Date:  2001-05-12

Review 3.  User procedure for self-measurement of blood pressure. First International Consensus Conference on Self Blood Pressure Measurement.

Authors:  T Mengden; B Chamontin; N Phong Chau; J Luis Palma Gamiz; X Chanudet
Journal:  Blood Press Monit       Date:  2000-04       Impact factor: 1.444

4.  Relationship between home blood pressure measurement and medication compliance and name recognition of antihypertensive drugs.

Authors:  T Ashida; T Sugiyama; S Okuno; A Ebihara; J Fujii
Journal:  Hypertens Res       Date:  2000-01       Impact factor: 3.872

5.  Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.

Authors:  K J Ball; P A Williams; K O Stumpe
Journal:  J Hypertens Suppl       Date:  2001-06

Review 6.  Telemonitoring of blood pressure self measurement in the OLMETEL study.

Authors:  Thomas Mengden; Silke Ewald; Stefanie Kaufmann; Johannes vor dem Esche; Sakir Uen; Hans Vetter
Journal:  Blood Press Monit       Date:  2004-12       Impact factor: 1.444

Review 7.  Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs.

Authors:  K O Stumpe; M Ludwig
Journal:  J Hum Hypertens       Date:  2002-05       Impact factor: 3.012

8.  Home self blood pressure measurement in general practice. The SMART study. Self-measurement for the Assessment of the Response to Trandolapril.

Authors:  G Chatellier; C Dutrey-Dupagne; L Vaur; F Zannad; N Genès; F Elkik; J Ménard
Journal:  Am J Hypertens       Date:  1996-07       Impact factor: 2.689

9.  Significance of blood pressure self-measurement as compared with office blood pressure measurement and ambulatory 24-hour blood pressure measurement in pharmacological studies.

Authors:  Thomas Mengden; Sakir Uen; Johannes Baulmann; Hans Vetter
Journal:  Blood Press Monit       Date:  2003-08       Impact factor: 1.444

Review 10.  Olmesartan medoxomil.

Authors:  Gregory T Warner; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more
  5 in total

1.  Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis.

Authors:  Joji Ishikawa; Deirdre J Carroll; Sujith Kuruvilla; Joseph E Schwartz; Thomas G Pickering
Journal:  Hypertension       Date:  2008-09-22       Impact factor: 10.190

2.  Self-blood pressure monitoring in an urban, ethnically diverse population: a randomized clinical trial utilizing the electronic health record.

Authors:  Stella S Yi; Bahman P Tabaei; Sonia Y Angell; Anne Rapin; Michael D Buck; William G Pagano; Frank J Maselli; Alvaro Simmons; Shadi Chamany
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-03-03

Review 3.  Systematic review of home telemonitoring for chronic diseases: the evidence base.

Authors:  Guy Paré; Mirou Jaana; Claude Sicotte
Journal:  J Am Med Inform Assoc       Date:  2007-02-28       Impact factor: 4.497

4.  [Possibilities of telemedicine in arterial hypertension].

Authors:  Walter Sehnert; Thomas Mengden
Journal:  Med Klin (Munich)       Date:  2009-04-15

Review 5.  Recommendations for home blood pressure monitoring in Latin American countries: A Latin American Society of Hypertension position paper.

Authors:  Raúl Villar; Ramiro A Sánchez; José Boggia; Ernesto Peñaherrera; Jesús Lopez; Weimar Sebba Barroso; Eduardo Barbosa; Leonardo Cobos; Rafael Hernández Hernández; José Andrés Octavio; José Z Parra Carrillo; Agustín J Ramírez; Gianfranco Parati
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-12       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.